Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

Rhea-AI Summary

Waters (NYSE: WAT) announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling U.S. commercialization for bloodstream infection and sepsis diagnostics. Clinical data showed a ~3-hour (~15%) faster mean time to detection versus the prior BD BACTEC FX system.

The fully automated platform offers automated gravimetric vial volume measurement, up to 60-vial automated loading (50% more than the leading competitor), and 480- or 960-vial configurations. The system is also available in Europe and Japan following CE marking and PMDA licensing.

Positive

• FDA 510(k) clearance enables BD BACTEC FXI U.S. commercialization
• Clinical study shows ~3-hour (~15%) faster time to detection vs prior system
• Automated loading of up to 60 vials, 50% more than leading competitor
• Scalable 480- and 960-vial capacity options for high-throughput labs
• Automated gravimetric vial volume measurement supports consistent diagnostics
• CE mark and Japan PMDA license expand availability to Europe and Japan

Negative

• None.

News Market Reaction – WAT

+2.11%

+2.11% News Effect

On the day this news was published, WAT gained 2.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FDA 510(k) clearance for the BD BACTEC FXI Culture System, offering abo...

Analysis

This announcement highlights FDA 510(k) clearance for the BD BACTEC FXI Culture System, offering about a 3-hour faster time to detection and higher vial capacity to support sepsis care. It reinforces Waters’ broader push into diagnostics following the BDS acquisition and complements recent high-end instrument launches. Investors may track adoption in high-throughput labs, revenue contribution relative to the $1.267 billion Q1 2026 base, and how Waters balances growth initiatives with its automatic shelf registration and elevated post‑deal leverage.

Key Figures

Time to detection: 17 hours vs 20 hours Detection time reduction: 3-hour (~15%) reduction Mortality increase per hour: 3.6% to 9.9% +5 more

8 metrics

Time to detection 17 hours vs 20 hours Mean time to detection vs prior-generation system in clinical study

Detection time reduction 3-hour (~15%) reduction Faster time to detection versus prior-generation system

Mortality increase per hour 3.6% to 9.9% Increase in sepsis mortality for each hour of delayed treatment

Vial loading increase 50% increase Increase in vial loading versus prior-generation/leading systems

Module capacity Up to 960 vials Maximum vial capacity per BD BACTEC FXI module

Automated loading capacity Up to 60 vials Automated loading capacity at a time for high-throughput labs

System configurations 480- and 960-vial Available BD BACTEC FXI Culture System configurations

Regulatory clearances FDA 510(k), CE mark, PMDA license Clearances for U.S., Europe and Japan availability

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Product launch	Positive	-1.4%	Launch of Cyclic IMS P20 MS for higher-sensitivity structural and spatial omics.
Jun 01	Product launch	Positive	-1.4%	Unveiling of Xevo MRT P10 MS benchtop HRMS with higher sensitivity and speed.
May 18	Conference appearance	Neutral	+1.2%	Announcement of CEO fireside chat at Jefferies Global Healthcare Conference.
May 05	Earnings results	Positive	+13.5%	Q1 2026 beat guidance and raised full‑year organic growth and EPS outlook.
Apr 20	Earnings call setup	Neutral	-0.1%	Scheduling of Q1 2026 earnings release and conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and technology launches have sometimes seen negative next-day moves despite seemingly positive news, while strong earnings with raised guidance saw a notable positive reaction.

Recent Company History

Over the past few months, Waters has combined transformative M&A with a stream of product and technology launches. Q1 2026 results showed net revenue of $1.267 billion and a strong positive stock reaction, after the company raised organic growth and EPS guidance. Subsequent news focused on advanced mass spectrometry platforms and conference participation, with mixed share-price responses. The current FDA 510(k) clearance for the BD BACTEC FXI Culture System fits the broader push into diagnostics and builds on the earlier acquisition of BD’s Biosciences & Diagnostic Solutions businesses.

Key Terms

510(k), sepsis, automated blood culture, antimicrobial therapy, +4 more

8 terms

510(k) regulatory

"FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

sepsis medical

"earlier targeted sepsis prevention"

Sepsis is a dangerous medical condition in which an infection triggers the body's defenses to damage its own tissues and organs, often leading to organ failure and emergency hospital care. For investors it matters because sepsis drives demand for diagnostics, antibiotics, intensive-care treatments and hospital resources, affects healthcare costs and insurer payouts, and can influence the commercial prospects and valuation of companies developing related tests, drugs and devices.

automated blood culture medical

"a fully automated blood culture system designed to improve the speed"

An automated blood culture is a lab test run by machines that continuously monitor blood samples for growing bacteria or fungi, flagging infections faster and with less manual checking than older methods. For investors, faster and more reliable detection shortens hospital stays, lowers treatment costs, and drives demand for the instruments, tests and software that companies sell, so adoption and performance of these systems can affect healthcare revenues and margins.

antimicrobial therapy medical

"more timely targeted antimicrobial therapy for patients with suspected bloodstream infections"

Antimicrobial therapy is treatment that uses drugs designed to kill or stop the growth of harmful microbes — such as bacteria, viruses, fungi or parasites — to cure or control infections. Investors care because the success, safety and availability of these drugs drive sales, affect regulatory approvals and shape long-term healthcare costs; think of them like replacing a failing lock to prevent repeated break‑ins, with resistance or failures harming future revenue and demand.

gram stain medical

"improving the availability of Gram stain and other tests, on which treatment decisions"

A gram stain is a quick laboratory test that colors bacteria to show whether their cell walls are thick or thin, classifying them as Gram-positive or Gram-negative. For investors, this matters because that basic distinction influences which antibiotics or diagnostics are likely to work, affects clinical trial design and regulatory reviews, and can change the commercial prospects of drug, diagnostic, and hospital-supply companies—like using a color code to pick the right tool for a job.

gravimetric measurement technical

"a first-of-its-kind capability ... an automated gravimetric measurement of individual blood culture vial volume"

Gravimetric measurement is the process of determining the amount of a substance by measuring its mass — essentially weighing what you have before and after a step to quantify how much is present or produced. For investors, it matters because these precise weight-based checks drive product quality, regulatory compliance, yield calculations and cost accuracy in manufacturing or lab work, much like using a kitchen scale to ensure a recipe turns out consistently.

CE marked regulatory

"was recently CE marked under the European Union's In Vitro Diagnostic Regulation"

CE marked indicates that a product meets European Union safety, health and environmental requirements and bears the CE symbol, acting like a safety stamp or passport that allows the product to be sold across the EU and European Economic Area. For investors, a CE mark matters because it reduces regulatory barriers and legal risk, can speed market access and revenue, and signals the company has cleared essential compliance steps for that product—affecting sales potential, costs and valuation.

in vitro diagnostic regulation (ivdr) regulatory

"CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR)"

A regulatory framework that sets rules for the safety, performance and market approval of laboratory tests and devices that analyze samples taken from the body (blood, saliva, tissue) rather than being used directly on patients. Think of it as building codes for diagnostic tests: it determines how hard it is and how long it takes for a test to get approved, how much testing and documentation companies must produce, and what ongoing controls are required. Investors care because those rules influence a maker’s cost, time to market, legal risk and ability to sell tests broadly, all of which affect revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.
• Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.
• Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.

MILFORD, Mass., June 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides a new option for laboratories seeking a fully automated blood culture system designed to improve the speed, consistency, and accuracy of sepsis and bloodstream infection diagnostics in modern microbiology laboratories.

Clinical study data¹ showed that the BD BACTEC FXI Culture System reduced mean time to detection by approximately three hours (~15%) compared with the previous-generation BD BACTEC™ FX Blood Culture System (17 hours vs. 20 hours). Faster detection enables earlier pathogen identification and more timely targeted antimicrobial therapy for patients with suspected bloodstream infections and sepsis. Because each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%,² faster diagnostic workflows are critical in acute care settings.

"Recent evidence-based laboratory guidelines document the beneficial clinical impact of rapid laboratory results for the detection of bloodstream infections; therefore, advancing the science of automated blood culture instruments is critical to further speed results," said Donna M. Wolk, MHA, Ph.D., D(ABMM), Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Laboratories. "Reducing the time to detection for positive results is key to improving the availability of Gram stain and other tests, on which treatment decisions are based. The faster, the better."

The BD BACTEC FXI Culture System features a first-of-its-kind capability in a blood culture platform – an automated gravimetric measurement of individual blood culture vial volume. By objectively confirming blood volume in each vial, the system reduces pre-analytical variability and supports more consistent diagnostics and adherence to recommended collection practices.

"Waters is proud to bring the BD BACTEC FXI Culture System to the U.S. market, delivering an important advancement in bloodstream infection diagnostics," said Jianqing Bennett, Senior Vice President, Waters Advanced Diagnostics, Waters Corporation. "This innovation reflects the scientific expertise and commitment of the Waters team to improve patient care. The system helps laboratories support earlier clinical decisions for patients with suspected sepsis and bloodstream infections when every hour matters."

Designed for high-throughput microbiology labs, the BD BACTEC FXI Culture System fully automates vial loading, unloading, incubation, and detection alerts, with an industry-leading automated loading capacity of up to 60 vials at a time,³ 50% more vials than the leading competitior.⁴ Available in 480- and 960-vial configurations,³ the BD BACTEC FXI Culture System delivers scalable efficiency while reducing manual intervention and increasing staff walk-away time.

The BD BACTEC FXI Culture System was recently CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR) and licensed by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for availability in Europe⁵ and Japan.⁶

Additional Resources:

The BD BACTEC FXI Culture System and BD BACTEC™ Blood Culture Vials are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries.

BD is a trademark of Becton, Dickinson and Company. Waters is a trademark of Waters Corporation or its affiliates. All other marks are the property of their respective owners.

About Waters Corporation:

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/aboutus. 

Disclaimer:

The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary: www.waters.com/bdtransaction. 

References:

1. Data on file BD, Clinical Performance Study Report IDS-23BACT002. Overall faster mean time to detection 2.8-hrs – 3.2-hrs compared to BD BACTEC FX Blood Culture System for BD BACTEC™ Plus Aerobic media and BD BACTEC™ Lytic Anaerobic media, respectively.
2. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-96. PMID 16625125.
3. Specification Data on File, Becton, Dickinson and Company 2026.
4. Specification data from BACT/ALERT® VIRTUO® 510(k) Substantial Equivalence Determination Decision Summary (K161816); page 5, Table J3.
5. Waters Press Release, April 15, 2026: https://www.prnewswire.com/news-releases/waters-announces-ce-mark-for-next-generation-fully-automated-bd-bactec-fxi-culture-system-for-bloodstream-infection-diagnosis-302743121.html.
6. Japan Pharmaceuticals and Medical Devices Agency (PMDA), License No. 13B1X10407.

Contact:

Molly Gluck
Head of External Communications
Waters Corporation
508.498.9732
molly_gluck@waters.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-announces-fda-510k-clearance-of-bd-bactec-fxi-culture-system-enabling-broader-access-to-bloodstream-infection-diagnostics-302789464.html

SOURCE Waters Corporation

FAQ

What did Waters (NYSE: WAT) announce about the BD BACTEC FXI Culture System on June 3, 2026?

Waters announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling commercialization in the U.S. According to Waters, the system targets faster, more consistent bloodstream infection and sepsis diagnostics in modern microbiology laboratories.

How much faster is the BD BACTEC FXI Culture System compared to the previous BD BACTEC FX system?

The BD BACTEC FXI Culture System reduced mean time to detection by about three hours versus the prior system. According to Waters, detection fell from 20 hours to 17 hours, about a 15% reduction that may support earlier targeted antimicrobial therapy.

What is the vial capacity and loading capability of the BD BACTEC FXI Culture System?

The system supports 480- or 960-vial configurations and automates loading of up to 60 vials at a time. According to Waters, this represents 50% more vials than the leading competitor and is designed to increase walk-away time in high-throughput labs.

How does the BD BACTEC FXI Culture System improve blood culture quality and consistency?

The BD BACTEC FXI Culture System adds automated gravimetric measurement of individual vial blood volume. According to Waters, confirming blood volume reduces pre-analytical variability, supports consistent diagnostics, and helps laboratories adhere to recommended blood collection practices.

In which regions is the BD BACTEC FXI Culture System available beyond the United States?

Beyond the U.S., the BD BACTEC FXI Culture System is available in Europe and Japan. According to Waters, it recently received a CE mark under EU IVDR for Europe and was licensed by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

Why is faster time to detection important for sepsis diagnostics with Waters’ BD BACTEC FXI system?

Faster detection supports earlier pathogen identification and more timely targeted antimicrobial therapy for suspected sepsis. According to Waters, each hour of delayed sepsis treatment can increase mortality by 3.6% to 9.9%, making accelerated diagnostic workflows critical in acute care settings.